Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

COPANLISIB for Diffuse large b-cell lymphoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 17 adverse event reports in the FDA FAERS database where COPANLISIB was used for Diffuse large b-cell lymphoma.

Most Reported Side Effects for COPANLISIB

Side Effect Reports % Deaths Hosp.
Pyrexia 58 16.3% 10 53
Off label use 43 12.1% 1 20
Hyperglycaemia 27 7.6% 2 18
Hypertension 24 6.8% 1 12
Rash maculo-papular 24 6.8% 4 16
Pneumonia 20 5.6% 6 15
Sepsis 19 5.4% 8 12
Diarrhoea 18 5.1% 2 5
Rash 16 4.5% 3 10
Febrile neutropenia 15 4.2% 6 8
Neutropenia 15 4.2% 3 5
Neutropenic sepsis 15 4.2% 2 14
Anaemia 14 3.9% 4 12
Dyspnoea 14 3.9% 6 12
Cytopenia 13 3.7% 0 11

Other Indications for COPANLISIB

Follicular lymphoma (42) B-cell lymphoma (38) Marginal zone lymphoma (29) Product used for unknown indication (23) Non-hodgkin's lymphoma recurrent (20) Non-hodgkin's lymphoma (11) B-cell lymphoma recurrent (10) Diffuse large b-cell lymphoma recurrent (10) Non-hodgkin's lymphoma unspecified histology indolent (6) Colorectal cancer (5)

Other Drugs Used for Diffuse large b-cell lymphoma

RITUXIMAB (22,275) CYCLOPHOSPHAMIDE (16,598) DOXORUBICIN (15,213) VINCRISTINE (14,922) PREDNISONE (11,266) LENALIDOMIDE (7,858) ETOPOSIDE (4,698) PREDNISOLONE (4,086) CYTARABINE (3,857) DEXAMETHASONE (3,696)

Related Pages

COPANLISIB Full Profile All Diffuse large b-cell lymphoma Drugs COPANLISIB Demographics COPANLISIB Timeline